The U.S. diabetes market is undergoing a rapid transformation, fueled by technological innovation, rising obesity rates, and growing demand for smarter, more personalized treatment options.
Valued at nearly $48 billion in 2024, the U.S. market for diabetes monitoring, treatment, and drug delivery is forecasted to reach $79 billion by 2031.
For investors, the space presents a unique blend of steady growth and disruptive innovation across monitoring, drug delivery, and wearable technology segments.
Table of Contents
➜ How Big Is the U.S. Diabetes Market?
➜ Key U.S. Diabetes Market Drivers and Limiters
↳ U.S. Diabetes Market Drivers
↳ U.S. Diabetes Market Limiters
➜ The Rise of GLP-1 Agonists and Next-Gen Insulin Devices
➜ New Diabetes Technology: Monitoring & Wearable Innovations
↳ CGM vs. Blood Glucose Meters
➜ Which Technology Would Be Best in Managing a Patient’s Diabetes?
➜ Competitive Landscape: Key Players in the U.S. Diabetes Market
➜ Future Outlook: Where Is the U.S. Diabetes Market Heading?
➜ Final Thoughts on The U.S. Diabetes Market
➜ Explore Our Comprehensive U.S. Diabetes Market Report Today
Key Takeaways:
- The U.S. diabetes market reached $48B in 2024 and is projected to hit $79B by 2031, driven by rising prevalence and new technologies.
- GLP-1 drugs like Ozempic® and Rybelsus® are disrupting traditional insulin markets with dual benefits for blood sugar and weight management.
- Smart insulin pens and AI-driven CGMs (e.g., Dexcom G7) are transforming diabetes care through real-time, personalized insights.
- Wearable technology is expanding rapidly, with CGMs expected to overtake glucose meters by 2030.
- Market leaders include Novo Nordisk, Eli Lilly, and Dexcom, each dominating key segments in treatment and monitoring.
- Growth is strong, but insurance limitations and regulatory hurdles remain key market challenges for advanced solutions.
How Big Is the U.S. Diabetes Market?
As of 2024, about 38 million Americans live with diabetes, a number that continues to rise annually. This creates sustained demand for medical devices, pharmaceuticals, and digital health platforms aimed at improving long-term management.
The largest and fastest-growing segment in 2024 was insulin and GLP-1 receptor agonists, representing the majority of total market value. Innovations in both injectables and oral formulations (e.g., Rybelsus®) are making these treatments more accessible, especially for type 2 diabetes and obesity management.
📌 Related Read:
Key U.S. Diabetes Market Drivers and Limiters
Market Drivers
- Obesity: Over 40% of U.S. adults are obese, significantly increasing diabetes prevalence.
- AI and Smart Tech: From predictive dosing algorithms to CGM-linked apps, AI is improving real-time diabetes control.
- Patient Demand: Consumers are increasingly opting for convenient, accurate, and minimally invasive solutions.
- Regulatory Pressure: Safety mandates are increasing the value of products like safety syringes and pens.
Market Limiters
- Limited Insurance Coverage: CGMs, insulin pumps, and smart pens remain costly for many patients.
- Regulatory Barriers: The FDA approval process for new tech and drugs is lengthy and expensive.
- Treatment Alternatives: GLP-1s and DPP-4 inhibitors are reducing reliance on traditional insulin therapy.
📌 Want to Learn More About The U.S. Diabetes Market in 2025? – Read:
➜ The Ultimate U.S. Diabetes Market Overview in 2025: Trends, Innovations, and Market Growth
The Rise of GLP-1 Agonists and Next-Gen Insulin Devices
GLP-1 drugs are revolutionizing type 2 diabetes care by offering blood sugar control, weight loss, and cardiovascular benefits. The approval of oral GLP-1 therapies like Rybelsus® marks a shift away from injection-only options and is broadening patient adoption.
Meanwhile, smart insulin pens like NovoPen® 6 and InPen® are offering connected, dose-tracking capabilities that align with digital health trends. These pens calculate dosage based on intake and integrate with mobile apps, improving compliance and decision-making.
📌 Learn More About Non-Injectable Diabetes Treatments in 2025 – Read:
➜ Non-Injectable Diabetes Medications and Treatments in 2025
New Diabetes Technology: Monitoring & Wearable Innovations
One of the most dynamic areas of growth lies in diabetes technology. Specifically, continuous glucose monitoring (CGM) and flash glucose monitoring (FGM) are replacing traditional blood glucose meters.
CGM vs. Blood Glucose Meters
| Feature | Continuous Glucose Monitoring (CGM) | Blood Glucose Meters (BGM) | Advantage |
| Data Frequency | Real-time readings every 1–5 minutes | Single data point per fingerstick | CGM |
| Patient Compliance | High – reduced need for manual input | Variable — requires frequent fingersticks | CGM |
| Accuracy (MARD) | ~9% (Dexcom G7, Libre 3) | ~10–15% depending on user error | CGM |
| Hypo/Hyper Alerts | Yes – customizable alerts with thresholds | No real-time alerts | CGM |
| Device Cost (2024 Avg.) | $3,000–$5,000/year | $300–$600/year (incl. strips) | BGM |
| Insurance Coverage | Improving – varies by provider | Widely covered | BGM |
| Market Adoption Trend | High growth – expected to surpass BGM by 2030 | Gradual decline in new users | CGM |
| Ease of Use for Elderly | Requires sensor insertion and app syncing | Familiar and simple for most patients | BGM |
Devices like Dexcom G7 and FreeStyle Libre are market leaders in this space, and CGM revenue is projected to surpass traditional meters by 2030.
Which Technology Would Be Best in Managing a Patient’s Diabetes?
For most patients, CGM combined with a smart insulin delivery device offers the most personalized and responsive form of diabetes management. These technologies allow for:
- Predictive low/high alerts
- Data sharing with healthcare providers
- AI-based dose calculation
- Mobile app integration
📌 Learn More About The Growth of CGM and FGM – Read:
Competitive Landscape: Key Players in the U.S. Diabetes Market
Novo Nordisk led the U.S. diabetes care market in 2024, driven by its dominance in ultra-long-acting and ultra-rapid-acting insulin, and its unique position as the sole player in the rapid-acting insulin segment. Its portfolio includes Levemir®, Tresiba®, Xultophy®, NovoRapid®, Fiasp®, NovoMix®, and Novolin®, along with leading GLP-1 products Ozempic® and Rybelsus®.
Eli Lilly ranked second, holding top positions in premixed, ultra-rapid-acting, and human insulin. Key products include Basaglar®, Humalog®, Humalog® Mix, and Humulin®, alongside its growing GLP-1 portfolio: Trulicity®, Mounjaro®, and Zepbound™.
Dexcom was the third-leading competitor, dominating the CGM segment with strong adoption of G6® and the FDA-approved G7®, reinforcing its leadership in diabetes monitoring.
- Novo Nordisk: Market leader in insulin and GLP-1s. Strong portfolio includes Ozempic®, Rybelsus®, and Fiasp®.
- Eli Lilly: Second-largest player, with Trulicity®, Mounjaro™, and Humalog®.
- Dexcom: Dominates the CGM space, with G7 now widely adopted.
- Abbott: Major competitor in FGM with FreeStyle Libre.
- Medtronic: Active in insulin pumps and AI-linked insulin delivery systems.
Future Outlook: Where Is the U.S. Diabetes Market Heading?
@diabe_tech Dexcom released the first Generative AI platform for a continuous glucose monitor. The platform analyzes glucose trends and lifestyle data to offer personalized tips to users. It’s available on Stelo first, but Dexcom hopes to introduce this to its entire line of CGMs. What are your hopes for AI on CGM? Tell us in the comments! ⬇️ . . . . #cgm #dexcom #dexcomstelo #stelo #dexcomg7 #diabetes #t1d #diabetic #typeone #type1 #typeonediabetes #typeonediabetic #type1diabetes #type1diabetic #diabetech
Looking ahead, the U.S. diabetes market will be shaped by:
- Broader CGM adoption
- Increased uptake of GLP-1s for both diabetes and obesity
- Expansion of smart wearable devices
- AI-driven personalized care plans
As AI continues to merge with real-time monitoring and drug delivery, we can expect to see more connected, autonomous, and patient-driven diabetes care solutions.
Final Thoughts on The U.S. Diabetes Market
With diabetes affecting over 1 in 10 Americans, the demand for smarter, faster, and more effective solutions is growing. For investors and innovators alike, understanding where the market is headed—and who is leading—is key to capitalizing on one of the most resilient and innovation-driven healthcare segments in the U.S.
📌 Read Our Full Ultimate U.S. Diabetes Market Overview in 2025
➜ The Ultimate U.S. Diabetes Market Overview in 2025: Trends, Innovations, and Market Growth
Explore Our Comprehensive U.S. Diabetes Market Report Today
Overall, the U.S. diabetes market was valued at nearly $48 billion in 2024 and is expected to increase significantly over the forecast period to reach up to $79 billion in 2031.
For an in-depth understanding of these trends, delve into our detailed 2025–2031 U.S. Diabetes Market Report. This report offers a comprehensive analysis of the U.S. Diabetes Market, covering:
Monitoring: Blood glucose meters, test strips, lancets, CGM, FGM
Treatment: Insulin, GLP-1 receptor agonists
Drug Delivery: Insulin pens, syringes, pumps, and more
Or request a complimentary U.S. Diabetes Market Executive Summary – completely free.
